Strategy of offering choice of CRC screening ups adherence

Share this article:
Strategy of Offering Choice of CRC Screening Ups Adherence
Strategy of Offering Choice of CRC Screening Ups Adherence

(HealthDay News) -- Adherence to colorectal cancer (CRC) screening varies based on the screening strategy, with adherence linked to patient preference and ethnicity/race, according to a study published in the April 9 issue of the Archives of Internal Medicine.

To investigate whether the approach by which screening is recommended influences adherence, John M. Inadomi, M.D., from the University of Washington in Seattle, and colleagues randomly allocated 997 individuals at average risk for development of CRC to receive recommendations for screening. Recommendations were received for fecal occult blood testing (FOBT), colonoscopy, or the patient's choice of FOBT or colonoscopy. The completion of screening within 12 months was assessed as the primary outcome.

The researchers found that 58 percent of participants completed the screening strategy they were assigned to or chose. Screening was completed by 38 percent of those who were recommended to colonoscopy, compared with 67 percent of those recommended to FOBT (P < 0.001) and 69 percent of those given a choice (P < 0.001). Screening was completed significantly more often by Latinos and Asians (primarily Chinese) compared with African-Americans. White participants adhered to colonoscopy more often and nonwhite participants adhered to FOBT more often.

"The common practice of universally recommending colonoscopy may reduce adherence to CRC screening, especially among racial/ethnic minorities," the authors write. "These results suggest that patient preferences should be considered when making CRC screening recommendations."

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Idelalisib approved by FDA for three types of blood cancer

Idelalisib approved by FDA for three types of ...

Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, but label warns drug may be toxic to the liver.

Physicians cautioned about counterfeit medical devices

Physicians cautioned about counterfeit medical devices

Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices.

Women undergoing morcellation have in 27 in 10k uterine cancer prevalence

Women undergoing morcellation have in 27 in 10k ...

For women undergoing hysterectomy by morcellation, the prevalence of uterine cancers is 27 per 10,000, with increased prevalence with advanced age, according to a research letter published online.